Business
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
TOKYO, February 18, 2026--Asahi Kasei Pharma in collaboration with Alchemedicine has announced that AK1960 has advanced to a Phase I clinical study.
About this update from Asahi Kasei Corporation
[{"type":"image","alt":"Asahi Kasei's Tokyo Headquarters","displaySize":"","headline":null,"caption":"Asahi Kasei's Tokyo Headquarters","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/8cdf2c65f8122bd426f4983db0a08378"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wsbXrWDAAO7JY_DSLLxX3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8cdf2c65f8122bd426f4983db0a08378","width":480,"height":320}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4999,"height":683,"url":"https://media.zenfs.com/en/business-wire.com/254971edc29f8d105999611e372bb9a0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NqA_BFjOCX7e9OidSEL.7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/254971edc29f8d105999611e372bb9a0","width":960,"height":131},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xDdlCt5HwDYK7XuR6mKNnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/254971edc29f8d105999611e372bb9a0","width":1200,"height":164}}},{"type":"text","content":"TOKYO, February 18, 2026--(BUSINESS WIRE)--Asahi Kasei Pharma, a global provider of healthcare and pharmaceutical solutions, in collaboration with Alchemedicine, has announced that its novel Endothelin A (ETA) receptor antagonist AK1960 has advanced to a Phase I clinical study following a successful preclinical phase. AK1960 is expected to be used in the treatment of various refractory diseases—medical conditions resistant to standard therapies. The initiation of a Phase I study is considered a significant step toward growing Asahi Kasei’s healthcare impact.","length":564,"tagName":"p"},{"type":"text","content":"AK1960 is a small molecule with a new core structure derived from Alchemedicine’s HiSAP™1 platform. It exhibits high selectivity, potent inhibition for the ETA receptor and has demonstrated efficacy in animal models for kidney diseases. AK1960 is expected to contribute to the treatment of various diseases which are difficult to control, such as refractory chronic kidney disease.","length":381,"tagName":"p"},{"type":"text","content":"In 2022,...